Fulcrum Therapeutics, Inc.
- FULC
- NASDAQ
- Biotechnology
- Genetic Disease Therapies
- Clinical-stage Biotech
$3.70
Today +1.37%Quote Oct 19, 2026, 08:00 PM UTC
−3.18%over the last month
Max drawdown −4.9%From 1-month high −4.9%3 months +0.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
9
Founded
2015
Market value
$282.3M
Quote Oct 19
Floor
$3.65
1.2% below price
Resistance
$3.74
1.1% above price
Price vs analyst targets
17 analysts
Lowest target
$3.00Highest target
$4.00
$3.00Highest target
$4.00
- Price $3.70
- Average target $3.60
- Analysts' target range
Analysts' average target sits about 3% lower.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FULCPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free